These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14667206)

  • 1. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.
    Kuruvilla J; Leitch HA; Vickars LM; Galbraith PF; Li CH; Al-Saab S; Naiman SC
    Eur J Haematol; 2003 Nov; 71(5):396-8. PubMed ID: 14667206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A soluble TNF-alpha receptor agent: etanercept].
    Kawai S
    Nihon Rinsho; 2005 May; 63 Suppl 5():741-6. PubMed ID: 15957219
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF agents for rheumatoid arthritis.
    Seymour HE; Worsley A; Smith JM; Thomas SH
    Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Etanercept].
    Takeuchi T; Amano K
    Nihon Rinsho; 2002 Dec; 60(12):2390-6. PubMed ID: 12510367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept: a review of its use in the management of rheumatoid arthritis.
    Dhillon S; Lyseng-Williamson KA; Scott LJ
    Drugs; 2007; 67(8):1211-41. PubMed ID: 17521223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
    Actis GC; Lagget M; Pellicano R; Rosina F
    Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.
    Yazici Y; Yazici H
    Clin Exp Rheumatol; 2008; 26(3):449-52. PubMed ID: 18578967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
    Pérez Pampín E; Gómez-Reino Carnota JJ
    Med Clin (Barc); 2008 Feb; 130(5):179-87. PubMed ID: 18341834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.